Peter Guenter

Peter Guenter

Director/Miembro de la Junta en IPSEN .

Fortuna: 14 300 $ al 31/05/2026

63 años
Health Technology
Consumer Services
Commercial Services

Perfil

Peter Guenter is currently Director at Ipsen SA since 2026, Director at Vicore Pharma Holding AB since 2026, and Director at the European Federation of Pharmaceutical Industries & Assns.
Formerly, Mr. Guenter was Chief Executive Officer & Director at Almirall SA from 2017 to 2020, Member-Management Board & CEO-Healthcare at Merck KGaA from 2021 to 2025, Chief Executive Officer at Merck Healthcare KGaA, Chairman-Supervisory Board at Sanofi-Aventis Deutschland GmbH, Independent Non-Executive Director at Lakefront Biotherapeutics from 2019 to 2025, EVP, General Manager-Diabetes & Cardiovascular at Sanofi from 2013 to 2017, and Executive Vice President at Smithkline Beecham.
Education includes graduation from Ghent University.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
31/12/2025 501 ( 0 % ) 14 300 $ 31/05/2026

Cargos activos de Peter Guenter

EmpresasCargoInicio
IPSEN Director/Miembro de la Junta 28/01/2026
VICORE PHARMA HOLDING AB Director/Miembro de la Junta 07/05/2026
Director/Miembro de la Junta -

Antiguos cargos conocidos de Peter Guenter.

EmpresasCargoFin
LAKEFRONT BIOTHERAPEUTICS NV Director/Miembro de la Junta 28/07/2025
MERCK KGAA Corporate Officer/Principal 01/06/2025
ALMIRALL, S.A. Director Ejecutivo 31/12/2020
SANOFI Corporate Officer/Principal 01/08/2017
Director Ejecutivo -
Ver el detalle de la experiencia de Peter Guenter.

Formación de Peter Guenter.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

62

Relaciones de 1er grado

11

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Commercial Services

Smithkline Beecham

Health Technology

Health Technology

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN